Daniel Ontaneda

Management of acute exacerbations in multiple sclerosis.

Intracranial atherosclerosis as a risk factor for ischemic stroke during open heart surgery.

Multiple sclerosis: new insights in pathogenesis and novel therapeutics.

Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720).

Metabolic syndrome in small fiber sensory neuropathy.

Early tolerability and safety of fingolimod in clinical practice.

Multiple sclerosis treatment: risk mitigation.

Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?

Sensitivity to volatile anesthetics in patients with dementia: a case-control analysis.

Benefits versus risks of latest therapies in multiple sclerosis: a perspective review.

Risk stratification and mitigation multiple sclerosis.

Experience with fingolimod in clinical practice.

Identifying the start of multiple sclerosis injury: a serial DTI study.

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Progressive multiple sclerosis.

Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Camptocormia and Pisa syndrome as manifestations of acute myasthenia gravis exacerbation.

Propensity methods for multiple sclerosis: The devil is in the details.

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Heterogeneous depression trajectories in multiple sclerosis patients.

Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging.

Imaging as an Outcome Measure in Multiple Sclerosis.

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - Commentary.

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Smokers with MS have greater decrements in quality of life and disability than non-smokers.

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.

T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

The challenges and opportunities of multiple sclerosis care in Latin America.

Clinical outcome measures for progressive MS trials.

Stem cell injection-induced glioneuronal lesion of the cauda equina.

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Automated Integration of Multimodal MRI for the Probabilistic Detection of the Central Vein Sign in White Matter Lesions.

Identifying a new subtype of multiple sclerosis.

Treatment decisions in MS: Shifting the goal posts or changing how we see them?

Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.

Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".

Multiple sclerosis risk factors contribute to onset heterogeneity.

MS progression is predominantly driven by age-related mechanisms - NO.

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

MOG-related disorders: A new cause of imaging-negative myelitis?

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.